New Delhi, 11 May 2022 – The Consumer Health division of Bayer announced the launch of the new and improved range of Canesten, thier anti-fungal treatment solution in India. Available in powder and cream formats, the product range offers anti-fungal properties that helps prevent and treat skin infections.
The multidisciplinary committee of experts, under the National Pharmaceutical Pricing Authority (NPPA), has said that it would desire to get a clarification of approval of license status from the manufacturers and markets of antifungal medication clotrimazole 1% mouth paint, in connection with fixation of ceiling price for the drug under the regulation.
Enforcement Report - Week of November 24, 2021
The multidisciplinary committee of experts, under the National Pharmaceutical Pricing Authority (NPPA) has said that the anti fungal medication clotrimazole 1% mouth paint is a scheduled formulation based on the Drugs (Price Control) Order, 2013.
Bayer Issues Voluntary Recall of Lotrimin and Tinactin Spray Products
WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer is voluntarily recalling all unexpired Lotrimin® AF and Tinactin® spray products with lot numbers beginning with TN, CV or NAA, distributed between September 2018 to September 2021, to the consumer level due to the presence of benzene in some samples of the products. Benzene is not an ingredient in any of Bayer Consumer Health products. It is important to note that Bayer’s decision to voluntarily recall these products is a precautionary measure and that the levels detected are not expected to cause adverse health consequences in consumers.
Bliss GVS Pharma Limited is on FDA Import Alert List
Pts Packers And Providers is on FDA Import Alert List
Health Canada Issues Recall Taro Pharmaceuticals `s Clotrimazole
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it has signed a definitive co-development and commercialization agreement (“Agreement”) with Alternavida S.A. de C.V. (“Alternavida”) for the clinical development, marketing and distribution of CAUMZTM (PPP011) in Mexico.